Table 2 Detailed parameters of MRI protocol in the included articles
Study ID | Field strength | Manufacturer | Dosage | Injection rate | The name and vendor of contrast agent | Spatial resolution | DCE phase | DCE acquisition time points or temporal resolution |
|---|---|---|---|---|---|---|---|---|
You et al. 2017 [14] | 1.5-T | Aurora Imaging Technology, Aurora Systems, Inc., Canada | NR | 2 mL / s | NR | In-plane spatial resolution = 1 mm | 1 pre- and 4 post-contrast acquisitions | At 90, 180, 270, and 360 s after injection |
Rella et al. 2020 [15] | 1.5-T | Signa® Excite; GE-medical system | 0.2 mL / kg | 2 mL / s | Gadobenate dimeglumine; MultiHance®, Bracco) | Pixel size = 0.7 mm2 | 1 pre- and 5 post-contrast acquisitions | NR |
Preibsch et al. 2016 [16] | 1.5-T | Philips Achieva, Hamburg, Germany | 0.16 mmol / kg | NR | Gadobutrol; Gadovist®, Bayer HealthCare AG, Berlin, Germany | In-plane spatial resolution = 0.8 mm | 1 pre- and 7 post-contrast acquisitions | NR (post-contrast images obtained at ~ 150 s were used for BPE analysis) |
Onishi et al. 2021 [19] | 1.5-T or 3.0-T | NR | NR | 2 mL / s | NR | In-plane spatial resolution ≤ 1.4 × 1.4 mm2 | 1 pre- and multiple post-contrast acquisitions | 80–100 s per dynamic acquisition |
Chen et al. 2015 [17] | 1.5-T | Philips Medical System, Best, Netherlands | 0.1 mmol / kg | NR | Omniscan; Nycomed-Amersham, Princeton, NJ | In-plane spatial resolution = (1.3–1.5) × (2.5–3.0) mm2 | 4 pre- and 12 post-contrast acquisitions | 42 s per dynamic acquisition |
Dong et al. 2018 [20] | 3.0-T | Skyra, Siemens, Munich, Germany | 0.2 mL / kg | 2.5 mL / s | Gadopentetate dimeglumine; Germany, Berlin, Schering Co, Ltd (SCHERING) | In-plane spatial resolution = 1.1 × 0.8 mm2 | 1 pre- and 7 post-contrast acquisitions | NR |
You et al. 2018 [21] | 1.5-T | Aurora Imaging Technology, Aurora Systems, Inc., Vancouver, Canada | NR | 2 mL / s | Magnevist; Bayer Schering Pharma, Berlin, Germany | In-plane spatial resolution = 1 mm | 1 pre- and 4 post-contrast acquisitions | At 90, 180, 270, and 360 s after injection |
Choi et al. 2015 [22] | 1.5-T or 3.0-T | Achieva; Philips Medical Systems, Best, The Netherlands / Magnetom Verio; Siemens Medical Solutions, Erlangen, Germany | 0.2 mmol / kg; 0.1 mmol / kg | NR | Gadovist; Bayer Schering Pharma AG | NR | 1 pre- and 6 post-contrast acquisitions | At 7, 67, 127, 187, 247, and 367 s after injection |
Arasu et al. 2020 [23] | 1.5-T or 3.0-T | NR | 0.1 mmol / kg | 2 mL / s | NR | In-plane spatial resolution ≤ 1.4 mm | Pre- and multiple post-contrast images | Continued for at least 8 min after injection |
Oh et al. 2018 [24] | 1.5-T | Magnetom Avanto; Siemens Healthcare, Erlangen, Germany | 0.1 mmol / kg; 0.2 mL / kg | 2 mL / s | Dotarem; Guerbet, Roissy, France / Magnevist; Bayer Schering Pharma, Berlin, Germany | 0.9 × 0.9 × 0.9 mm3 | 1 pre- and 5 post-contrast acquisitions | 61 s per dynamic acquisition |
La Forgia et al. 2021 [25] | 1.5-T | Achieva, Philips Medical Systems, Best, The Netherlands | 0.1 mmol / kg | 2–2.5 mL / s | NR | 1.5 × 1.5 × 1.5 mm3 | 1 pre- and 5 post-contrast acquisitions | 60 s per dynamic acquisition |
Teixeira et al. 2018 [18] | 1.5-T | Achieva; Philips Medical Systems, Best, the Netherlands | 0.1 mmol / kg | NR | NR | NR | 1 pre- and 3 post-contrast acquisitions | NR |
Moliere et al. 2019 [26] | 1.5-T | Aera, Siemens Healthcare | 0.1 mmol / kg | NR | Dotarem; Guerbet, Roissy, France | NR | 1 pre- and 5 post-contrast acquisitions | 90 s per dynamic acquisition; the late acquisition was centered at 6 min |